Login
Zynerba Pharmaceuticals NASDAQ: ZYNE
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
| Name | Zynerba Pharmaceuticals |
| Ticker | ZYNE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
|
Price
52W Low/High |
5.51
3.23 / 8.76 |
| Momentum | Strong Up |
| Market cap | 227 M |
| 1Y Total Return |
-12.95%
Subpar |
| 1Y Volatility |
120.94%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
Details
| Ticker | ZYNE |
| Name | Zynerba Pharmaceuticals |
| ISIN | US98986X1090 |
| CUSIP | 98986X109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 6/21/2021
| Close Price | 5.51 |
| 52W Low/High | 3.23 / 8.76 |
| Market cap | 227 M |
| 1Y Total Return |
-12.95%
Subpar |
| 1Y Volatility |
120.94%
High Risk |
| Beta | 4.31 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -3.07 |
| Diluted Earnings / Share | -1.60 |
| ROE | - |
| ROIC | -1,082.1% |
| Price / Revenue | - |
| Price / Book | 2.3 |
| Price / CF | -5.7 |
| Current Ratio | 8.5 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | 0.01 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
-
|
-
|
0
|
-
|
-
|
0
|
|
| R&D |
33
|
21
|
25
|
26
|
20
|
9
|
|
| EBITDA |
-47
|
-36
|
-37
|
-37
|
-26
|
-15
|
|
| Operating Income |
-49
|
-36
|
-37
|
-38
|
-27
|
-15
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
40
|
23
|
19
|
13
|
12
|
9
|
|
| EPS exc. Extra |
-1.60
|
-1.58
|
-2.23
|
-2.79
|
-2.69
|
-2.72
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
109
|
76
|
76
|
60
|
85
|
39
|
|
| Cash, Eq & Invt ShortTerm |
93
|
61
|
68
|
52
|
77
|
37
|
|
| Total Current Assets |
107
|
75
|
74
|
58
|
83
|
39
|
|
| Total Non-Current Assets |
2
|
1
|
1
|
2
|
1
|
1
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
13
|
10
|
7
|
10
|
7
|
3
|
|
| Total Current Liabilities |
13
|
10
|
7
|
9
|
7
|
3
|
|
| Long Term Debt |
1
|
0
|
0
|
1
|
0
|
0
|
|
| Shareholder equity |
96
|
66
|
68
|
50
|
78
|
36
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-39
|
-36
|
-32
|
-29
|
-23
|
-13
|
|
| Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing |
-0
|
-0
|
-0
|
-0
|
-0
|
-0
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing |
71
|
29
|
48
|
3
|
64
|
42
|
|
| Stock Issued |
73
|
30
|
51
|
3
|
64
|
42
|
|
| Debt (LT) Issued |
-2
|
-1
|
-3
|
-0
|
0
|
0
|
|
| Free Cash Flow |
-45
|
-33
|
-38
|
-35
|
-22
|
-
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
8.5
|
7.3
|
9.9
|
6.5
|
12.0
|
13.2
|
|
| Financial Leverage D/E |
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-1,082.1%
|
-1,358.0%
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available